Siemens Healthineers raises outlook on demand for rapid Covid tests

[BERLIN] German health technology company Siemens Healthineers raised its full-year sales and profit forecast on Monday, as the global Covid-19 pandemic continues to drive demand for its rapid antigen tests.

The medical technology group now expects sales to grow 14 per cent-17 per cent in the year to September, up from a previous forecast for a rise of 8 per cent-12 per cent.

Adjusted basic earnings per share are seen at 1.90-2.05 (S$3.04 - S$3.28) euros versus an earlier forecast of 1.63-1.82 euros.

Siemens Healthineers said it now expected rapid antigen test revenues of around 750 million euros in 2021, up from 300-350 million previously forecast.

Sales in the January-March period, Siemens Healthineers' fiscal second quarter, rose to 7.6 per cent to 3.965 billion euros, while net income increased 8 per cent to 447 million euros.

REUTERS